| REVISIONS TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS |
NOTE
3 – REVISIONS TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS
The
Company is revising its previously issued financial statements to correct for errors identified associated with the calculation of telehealth
revenue, cost of telehealth revenue, general and administrative expenses, accounts receivable, deferred revenue and accrued expenses.
The Company has evaluated these errors in accordance with ASC 650-10-S99 and S55 (formerly Staff Accounting Bulletins (“SAB”)
No. 99 and No. 108), Accounting Changes and Error Corrections.
During
the three months ended September 30, 2026, the Company identified additional errors related to the recording of net revenue as agent
and associated expenses in certain arrangements with the Company’s third-party pharmacy providers,
which resulted in the misstatement of telehealth revenue, cost of telehealth revenue, general and administrative expenses and the
related balance sheet accounts in its previously issued 2024 and 2025 annual and interim financial statements, and 2026 interim
financial statements. Although the Company has determined such errors to be immaterial to its previously issued financial
statements, the Company will revise its previously issued financial statements to correct these errors.
In
addition, the Company corrected prior period errors as out-of-period adjustments included in its previously issued March 31, 2026 financial
statements that were deemed to be quantitatively and qualitatively immaterial, individually and in the aggregate, to the financial statements
in the periods recorded or to the relevant prior periods. However, as the Company is revising its previously issued financial statements
to correct for the newly identified errors discussed above, the Company has corrected these errors in its financial statements in the
periods to which they relate in connection with the revision described above.
The
Company will effect such revisions to its consolidated balance sheet as of December 31, 2025 and its consolidated statement of operations,
consolidated statement of changes in stockholders’ (deficit) equity and consolidated statement of cash flows for the years ended
December 31, 2025 and December 31, 2024 in connection with the future filing of its 2026 Annual Report on Form 10-K, which will include these
comparative periods and will affect the revisions for the three months ended March 31, 2026 and the three and six months ended June 30,
2026 in connection with the future filings of its Form 10-Q which will include these comparative periods. The following tables present the
effect of the revisions on the financial statements previously issued as of and for the year ended December 31, 2025, for the year ended
December 31, 2024, for the three months ended September 30, 2025, for the nine months ended September 30, 2025, for
the three months ended March 31, 2026, for the three months ended June 30, 2026 and for the six months ended June 30, 2026
as a result of the error corrections described above.
As
discussed in Note 4—Discontinued Operations, WorkSimpli has been treated as discontinued operations for all periods presented.
As a result, the “As Revised” figures for the three and nine months ended September 30, 2025 were recast for the impact of
discontinued operations to arrive at “As Revised and Recast” figures as presented throughout these consolidated financial
statements.
SCHEDULE
OF REVISION ON THE PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
As of December 31, 2025 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Consolidated Balance Sheet: | |
| | | |
| | | |
| | |
| Accounts receivable | |
$ | 9,305,277 | | |
$ | (6,819,395 | ) | |
$ | 2,485,882 | |
| Total Current Assets | |
$ | 51,831,465 | | |
$ | (6,819,395 | ) | |
$ | 45,012,070 | |
| Total Assets | |
$ | 70,411,319 | | |
$ | (6,819,395 | ) | |
$ | 63,591,924 | |
| Accrued expenses | |
$ | 15,974,016 | | |
$ | (1,759,623 | ) | |
$ | 14,214,393 | |
| Deferred revenue | |
$ | 10,807,773 | | |
$ | (234,331 | ) | |
$ | 10,573,442 | |
| Total Current Liabilities | |
$ | 41,573,365 | | |
$ | (1,993,954 | ) | |
$ | 39,579,411 | |
| Total Liabilities | |
$ | 47,254,739 | | |
$ | (1,993,954 | ) | |
$ | 45,260,785 | |
| Accumulated deficit | |
$ | 228,603,075 | | |
$ | 4,825,441 | | |
$ | 233,428,516 | |
| Total LifeMD, Inc. Stockholders’ Equity | |
$ | 23,156,580 | | |
$ | (4,825,441 | ) | |
$ | 18,331,139 | |
| Total Stockholders’ Equity | |
$ | 23,156,580 | | |
$ | (4,825,441 | ) | |
$ | 18,331,139 | |
| Total Liabilities and Stockholder’s Equity | |
$ | 70,411,319 | | |
$ | (6,819,395 | ) | |
$ | 63,591,924 | |
| | |
| | | |
| | | |
| | |
| | |
For the Year Ended December 31, 2025 | |
| | |
As Previously
Reported | | |
Adjustment | | |
As Revised | |
| Consolidated Statement of Operations: | |
| | | |
| | | |
| | |
| Telehealth revenue, net | |
$ | 194,055,198 | | |
$ | (237,006 | ) | |
$ | 193,818,192 | |
| Cost of telehealth revenue | |
$ | 27,714,808 | | |
$ | 477,194 | | |
$ | 28,192,002 | |
| Gross profit | |
$ | 166,340,390 | | |
$ | (714,200 | ) | |
$ | 165,626,190 | |
| General and administrative expenses | |
$ | 57,937,023 | | |
$ | 753,762 | | |
$ | 58,690,785 | |
| Total expenses | |
$ | 174,010,084 | | |
$ | 753,762 | | |
$ | 174,763,846 | |
| Operating loss from continuing operations | |
$ | (7,669,694 | ) | |
$ | (1,467,962 | ) | |
$ | (9,137,656 | ) |
| Net loss from continuing operations | |
$ | (10,232,233 | ) | |
$ | (1,467,962 | ) | |
$ | (11,700,195 | ) |
| Net income | |
$ | 15,619,791 | | |
$ | (1,467,962 | ) | |
$ | 14,151,829 | |
| Net income attributable to LifeMD, Inc. | |
$ | 14,354,106 | | |
$ | (1,467,962 | ) | |
$ | 12,886,144 | |
| Net income attributable to LifeMD, Inc. common stockholders | |
$ | 11,247,856 | | |
$ | (1,467,962 | ) | |
$ | 9,779,894 | |
| Basic earnings per share attributable to LifeMD, Inc. common stockholders | |
$ | 0.25 | | |
$ | (0.03 | ) | |
$ | 0.22 | |
| Diluted earnings per share attributable to LifeMD, Inc. common stockholders | |
$ | 0.25 | | |
$ | (0.03 | ) | |
$ | 0.22 | |
| Consolidated Statement of Changes in Stockholders’ (Deficit) Equity: | |
| | | |
| | | |
| | |
| Accumulated deficit | |
$ | 228,603,075 | | |
$ | 4,825,441 | | |
$ | 233,428,516 | |
| Consolidated Statement of Cash Flows: | |
| | | |
| | | |
| | |
| Net loss from continuing operations | |
$ | (10,232,233 | ) | |
$ | (1,467,962 | ) | |
$ | (11,700,195 | ) |
| Accounts receivable | |
$ | 1,150,536 | | |
$ | 2,348,242 | | |
$ | 3,498,778 | |
| Deferred revenue | |
$ | (6,290,081 | ) | |
$ | 38,894 | | |
$ | (6,251,187 | ) |
| Accrued expenses | |
$ | (5,782,603 | ) | |
$ | (919,174 | ) | |
$ | (6,701,777 | ) |
| Net cash provided by operating activities of continuing operations | |
$ | 2,072,304 | | |
$ | - | | |
$ | 2,072,304 | |
| Net cash provided by operating activities | |
$ | 8,280,175 | | |
$ | - | | |
$ | 8,280,175 | |
| | |
As Previously
Reported | | |
Adjustment | | |
As Revised | |
| | |
For the Year Ended December 31, 2024 | |
| | |
As Previously
Reported | | |
Adjustment | | |
As Revised | |
| Consolidated Statement of Operations: | |
| | |
| | |
| |
| Telehealth revenue, net | |
$ | 154,824,075 | | |
$ | (1,979,194 | ) | |
$ | 152,844,881 | |
| Cost of telehealth revenue | |
$ | 21,440,799 | | |
$ | 655,127 | | |
$ | 22,095,926 | |
| Gross profit | |
$ | 133,383,276 | | |
$ | (2,634,321 | ) | |
$ | 130,748,955 | |
| General and administrative expenses | |
$ | 57,947,932 | | |
$ | 685,656 | | |
$ | 58,633,588 | |
| Total expenses | |
$ | 153,785,264 | | |
$ | 685,656 | | |
$ | 154,470,920 | |
| Operating loss from continuing operations | |
$ | (20,401,988 | ) | |
$ | (3,319,977 | ) | |
$ | (23,721,965 | ) |
| Net loss from continuing operations | |
$ | (23,175,393 | ) | |
$ | (3,319,977 | ) | |
$ | (26,495,370 | ) |
| Net loss | |
$ | (20,860,141 | ) | |
$ | (3,319,977 | ) | |
$ | (24,180,118 | ) |
| Net loss attributable to LifeMD, Inc. | |
$ | (21,409,016 | ) | |
$ | (3,319,977 | ) | |
$ | (24,728,993 | ) |
| Net loss attributable to LifeMD, Inc. common stockholders | |
$ | (24,515,266 | ) | |
$ | (3,319,977 | ) | |
$ | (27,835,243 | ) |
| Basic loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.60 | ) | |
$ | (0.08 | ) | |
$ | (0.68 | ) |
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.60 | ) | |
$ | (0.08 | ) | |
$ | (0.68 | ) |
| Consolidated Statement of Changes in Stockholders’ (Deficit) Equity: | |
| | | |
| | | |
| | |
| Accumulated deficit | |
$ | 239,850,931 | | |
$ | 3,357,479 | | |
$ | 243,208,410 | |
| Consolidated Statement of Cash Flows: | |
| | | |
| | | |
| | |
| Net loss from continuing operations | |
$ | (23,175,393 | ) | |
$ | (3,319,977 | ) | |
$ | (26,495,370 | ) |
| Accounts receivable | |
$ | (4,487,546 | ) | |
$ | 4,471,153 | | |
$ | (16,393 | ) |
| Deferred revenue | |
$ | 9,826,219 | | |
$ | (273,225 | ) | |
$ | 9,552,994 | |
| Accrued expenses | |
$ | 10,755,261 | | |
$ | (877,951 | ) | |
$ | 9,877,310 | |
| Net cash provided by operating activities of continuing operations | |
$ | 14,363,313 | | |
$ | - | | |
$ | 14,363,313 | |
| Net cash provided by operating activities | |
$ | 17,513,190 | | |
$ | - | | |
$ | 17,513,190 | |
| | |
As Previously
Reported | | |
Adjustment | | |
As Revised | | |
Discontinued
Operations | | |
As Revised
and Recast | |
| | |
For the Three Months Ended September 30, 2025 | |
| | |
As Previously
Reported | | |
Adjustment | | |
As Revised | | |
Discontinued
Operations | | |
As Revised
and Recast | |
| Consolidated Statement of Operations: | |
| | | |
| | | |
| | | |
| | | |
| | |
| Telehealth revenue, net | |
$ | 47,279,933 | | |
$ | 448,009 | | |
$ | 47,727,942 | | |
$ | - | | |
$ | 47,727,942 | |
| Cost of telehealth revenue | |
$ | 6,714,235 | | |
$ | 347,416 | | |
$ | 7,061,651 | | |
$ | - | | |
$ | 7,061,651 | |
| Gross profit | |
$ | 52,764,557 | | |
$ | 100,593 | | |
$ | 52,865,150 | | |
$ | 12,198,859 | | |
$ | 40,666,291 | |
| General and administrative expenses | |
$ | 16,589,390 | | |
$ | 183,902 | | |
$ | 16,773,292 | | |
$ | 2,972,915 | | |
$ | 13,800,377 | |
| Total expenses | |
$ | 54,733,771 | | |
$ | 183,902 | | |
$ | 54,917,673 | | |
$ | 11,124,700 | | |
$ | 43,792,973 | |
| Operating loss from continuing operations | |
$ | (1,969,214 | ) | |
$ | (83,309 | ) | |
$ | (2,052,523 | ) | |
$ | 1,074,159 | | |
$ | (3,126,682 | ) |
| Net loss from continuing operations | |
$ | (3,556,655 | ) | |
$ | (83,309 | ) | |
$ | (3,639,964 | ) | |
$ | 935,013 | | |
$ | (4,574,977 | ) |
| Net loss | |
$ | (3,556,655 | ) | |
$ | (83,309 | ) | |
$ | (3,639,964 | ) | |
$ | - | | |
$ | (3,639,964 | ) |
| Net loss attributable to LifeMD, Inc. | |
$ | (3,806,117 | ) | |
$ | (83,309 | ) | |
$ | (3,889,426 | ) | |
$ | - | | |
$ | (3,889,426 | ) |
| Net loss attributable to LifeMD, Inc. common stockholders | |
$ | (4,582,680 | ) | |
$ | (83,309 | ) | |
$ | (4,665,989 | ) | |
$ | - | | |
$ | (4,665,989 | ) |
| Basic loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.10 | ) | |
$ | - | | |
$ | (0.10 | ) | |
$ | - | | |
$ | (0.10 | ) |
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.10 | ) | |
$ | - | | |
$ | (0.10 | ) | |
$ | - | | |
$ | (0.10 | ) |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | | |
Discontinued
Operations | | |
As Revised
and Recast | |
| | |
For the Nine Months Ended September 30, 2025 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | | |
Discontinued
Operations | | |
As Revised
and Recast | |
| Consolidated Statement of Operations: | |
| | | |
| | | |
| | | |
| | | |
| | |
| Telehealth revenue, net | |
$ | 147,186,714 | | |
$ | (325,017 | ) | |
$ | 146,861,697 | | |
$ | - | | |
$ | 146,861,697 | |
| Cost of telehealth revenue | |
$ | 21,689,400 | | |
$ | (61,499 | ) | |
$ | 21,627,901 | | |
$ | - | | |
$ | 21,627,901 | |
| Gross profit | |
$ | 163,492,506 | | |
$ | (263,518 | ) | |
$ | 163,228,988 | | |
$ | 37,995,192 | | |
$ | 125,233,796 | |
| General and administrative expenses | |
$ | 51,210,246 | | |
$ | 599,487 | | |
$ | 51,809,733 | | |
$ | 8,814,478 | | |
$ | 42,995,255 | |
| Total expenses | |
$ | 164,938,940 | | |
$ | 599,487 | | |
$ | 165,538,427 | | |
$ | 32,869,650 | | |
$ | 132,668,777 | |
| Operating loss from continuing operations | |
$ | (1,446,434 | ) | |
$ | (863,005 | ) | |
$ | (2,309,439 | ) | |
$ | 5,125,542 | | |
$ | (7,434,981 | ) |
| Net loss from continuing operations | |
$ | (4,323,177 | ) | |
$ | (863,005 | ) | |
$ | (5,186,182 | ) | |
$ | 4,821,519 | | |
$ | (10,007,701 | ) |
| Net loss | |
$ | (4,323,177 | ) | |
$ | (863,005 | ) | |
$ | (5,186,182 | ) | |
$ | - | | |
$ | (5,186,182 | ) |
| Net loss attributable to LifeMD, Inc. | |
$ | (5,609,559 | ) | |
$ | (863,005 | ) | |
$ | (6,472,564 | ) | |
$ | - | | |
$ | (6,472,564 | ) |
| Net loss attributable to LifeMD, Inc. common stockholders | |
$ | (7,939,247 | ) | |
$ | (863,005 | ) | |
$ | (8,802,252 | ) | |
$ | - | | |
$ | (8,802,252 | ) |
| Basic loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.18 | ) | |
$ | (0.02 | ) | |
$ | (0.20 | ) | |
$ | - | | |
$ | (0.20 | ) |
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.18 | ) | |
$ | (0.02 | ) | |
$ | (0.20 | ) | |
$ | - | | |
$ | (0.20 | ) |
| Consolidated Statement of Changes in Stockholders’ (Deficit) Equity: | |
| | | |
| | | |
| | | |
| | | |
| | |
| Accumulated deficit | |
$ | 247,790,178 | | |
$ | 4,220,483 | | |
$ | 252,010,661 | | |
$ | - | | |
$ | 252,010,661 | |
| Consolidated Statement of Cash Flows: | |
| | | |
| | | |
| | | |
| | | |
| | |
| Net loss from continuing operations | |
$ | (4,323,177 | ) | |
$ | (863,005 | ) | |
$ | (5,186,182 | ) | |
$ | 4,821,519 | | |
$ | (10,007,701 | ) |
| Accounts receivable | |
$ | 1,609,763 | | |
$ | 1,103,965 | | |
$ | 2,713,728 | | |
$ | 95,332 | | |
$ | 2,618,396 | |
| Deferred revenue | |
$ | (5,270,408 | ) | |
$ | 85,117 | | |
$ | (5,185,291 | ) | |
$ | (320,553 | ) | |
$ | (4,864,738 | ) |
| Accrued expenses | |
$ | (731,959 | ) | |
$ | (326,077 | ) | |
$ | (1,058,036 | ) | |
$ | 51,903 | | |
$ | (1,109,939 | ) |
| Net cash provided by operating activities of continuing operations | |
$ | 11,560,698 | | |
$ | - | | |
$ | 11,560,698 | | |
$ | 7,390,125 | | |
$ | 4,170,573 | |
| Net cash provided by operating activities | |
$ | 11,560,698 | | |
$ | - | | |
$ | 11,560,698 | | |
$ | - | | |
$ | 11,560,698 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
For the Three Months Ended March 31, 2026 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Consolidated Statement of Operations: | |
| | | |
| | | |
| | |
| Telehealth revenue, net | |
$ | 50,162,956 | | |
$ | 357,399 | | |
$ | 50,520,355 | |
| Cost of telehealth revenue | |
$ | 5,925,499 | | |
$ | 146,586 | | |
$ | 6,072,085 | |
| Gross profit | |
$ | 44,237,457 | | |
$ | 210,813 | | |
$ | 44,448,270 | |
| General and administrative expenses | |
$ | 15,176,355 | | |
$ | (168,611 | ) | |
$ | 15,007,744 | |
| Total expenses | |
$ | 53,166,529 | | |
$ | (168,611 | ) | |
$ | 52,997,918 | |
| Operating loss from continuing operations | |
$ | (8,929,072 | ) | |
$ | 379,424 | | |
$ | (8,549,648 | ) |
| Net loss from continuing operations | |
$ | (8,872,596 | ) | |
$ | 379,424 | | |
$ | (8,493,172 | ) |
| Net loss | |
$ | (8,872,596 | ) | |
$ | 379,424 | | |
$ | (8,493,172 | ) |
| Net loss attributable to LifeMD, Inc. | |
$ | (8,872,596 | ) | |
$ | 379,424 | | |
$ | (8,493,172 | ) |
| Net loss attributable to LifeMD, Inc. common stockholders | |
$ | (9,649,159 | ) | |
$ | 379,424 | | |
$ | (9,269,735 | ) |
| Basic loss per share from continuing operations attributable to LifeMD, Inc. common stockholders | |
$ | (0.20 | ) | |
$ | - | | |
$ | (0.20 | ) |
| Diluted loss per share from continuing operations attributable to LifeMD, Inc. common stockholders | |
$ | (0.20 | ) | |
$ | - | | |
$ | (0.20 | ) |
| Consolidated Statement of Changes in Stockholders’ (Deficit) Equity: | |
| | | |
| | | |
| | |
| Accumulated deficit | |
$ | 238,252,234 | | |
$ | 4,446,017 | | |
$ | 242,698,251 | |
| Consolidated Statement of Cash Flows: | |
| | | |
| | | |
| | |
| Net loss | |
$ | (8,872,596 | ) | |
$ | 379,424 | | |
$ | (8,493,172 | ) |
| Accounts receivable | |
$ | (549,840 | ) | |
$ | 90,112 | | |
$ | (459,728 | ) |
| Deferred revenue | |
$ | 1,209,067 | | |
$ | 234,331 | | |
$ | 1,443,398 | |
| Accrued expenses | |
$ | (729,053 | ) | |
$ | (703,867 | ) | |
$ | (1,432,920 | ) |
| Net cash provided by operating activities | |
$ | 444,624 | | |
$ | - | | |
$ | 444,624 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
For the Three Months Ended June 30, 2026 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Consolidated Statement of Operations: | |
| | | |
| | | |
| | |
| Telehealth revenue, net | |
$ | 47,281,085 | | |
$ | (377,678 | ) | |
$ | 46,903,407 | |
| Gross profit | |
$ | 41,996,762 | | |
$ | (377,678 | ) | |
$ | 41,619,084 | |
| General and administrative expenses | |
$ | 13,645,809 | | |
$ | 160,584 | | |
$ | 13,806,393 | |
| Total expenses | |
$ | 49,126,363 | | |
$ | 160,584 | | |
$ | 49,286,947 | |
| Operating loss from continuing operations | |
$ | (7,129,601 | ) | |
$ | (538,262 | ) | |
$ | (7,667,863 | ) |
| Net loss from continuing operations | |
$ | (7,083,941 | ) | |
$ | (538,262 | ) | |
$ | (7,622,203 | ) |
| Net loss | |
$ | (7,083,941 | ) | |
$ | (538,262 | ) | |
$ | (7,622,203 | ) |
| Net loss attributable to LifeMD, Inc. | |
$ | (7,083,941 | ) | |
$ | (538,262 | ) | |
$ | (7,622,203 | ) |
| Net loss attributable to LifeMD, Inc. common stockholders | |
$ | (7,860,503 | ) | |
$ | (538,262 | ) | |
$ | (8,398,765 | ) |
| Basic loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.16 | ) | |
$ | (0.02 | ) | |
$ | (0.18 | ) |
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.16 | ) | |
$ | (0.02 | ) | |
$ | (0.18 | ) |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| | |
For the Six Months Ended June 30, 2026 | |
| | |
As Previously Reported | | |
Adjustment | | |
As Revised | |
| Consolidated Statement of Operations: | |
| | | |
| | | |
| | |
| Telehealth revenue, net | |
$ | 97,444,041 | | |
$ | (20,279 | ) | |
$ | 97,423,762 | |
| Cost of telehealth revenue | |
$ | 11,209,822 | | |
$ | 146,586 | | |
$ | 11,356,408 | |
| Gross profit | |
$ | 86,234,219 | | |
$ | (166,865 | ) | |
$ | 86,067,354 | |
| General and administrative expenses | |
$ | 28,822,164 | | |
$ | (8,027 | ) | |
$ | 28,814,137 | |
| Total expenses | |
$ | 102,292,892 | | |
$ | (8,027 | ) | |
$ | 102,284,865 | |
| Operating loss from continuing operations | |
$ | (16,058,673 | ) | |
$ | (158,838 | ) | |
$ | (16,217,511 | ) |
| Net loss from continuing operations | |
$ | (15,956,537 | ) | |
$ | (158,838 | ) | |
$ | (16,115,375 | ) |
| Net loss | |
$ | (15,956,537 | ) | |
$ | (158,838 | ) | |
$ | (16,115,375 | ) |
| Net loss attributable to LifeMD, Inc. | |
$ | (15,956,537 | ) | |
$ | (158,838 | ) | |
$ | (16,115,375 | ) |
| Net loss attributable to LifeMD, Inc. common stockholders | |
$ | (17,509,662 | ) | |
$ | (158,838 | ) | |
$ | (17,668,500 | ) |
| Basic loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.37 | ) | |
$ | - | | |
$ | (0.37 | ) |
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | |
$ | (0.37 | ) | |
$ | - | | |
$ | (0.37 | ) |
| Consolidated Statement of Changes in Stockholders’ (Deficit) Equity: | |
| | | |
| | | |
| | |
| Accumulated deficit | |
$ | 246,112,737 | | |
$ | 4,984,279 | | |
$ | 251,097,016 | |
| Consolidated Statement of Cash Flows: | |
| | | |
| | | |
| | |
| Net loss | |
$ | (15,956,537 | ) | |
$ | (158,838 | ) | |
$ | (16,115,375 | ) |
| Accounts receivable | |
$ | (1,950,881 | ) | |
$ | 694,776 | | |
$ | (1,256,105 | ) |
| Deferred revenue | |
$ | (16,552 | ) | |
$ | 234,331 | | |
$ | 217,779 | |
| Accrued expenses | |
$ | 987,170 | | |
$ | (770,269 | ) | |
$ | 216,901 | |
| Net cash used in operating activities | |
$ | (6,481,023 | ) | |
$ | - | | |
$ | (6,481,023 | ) |
These
accompanying notes to the unaudited consolidated financial statements reflect the impact of this revision.
|